U.S. top court rejects hepatitis B drug patent case

May 4, 2015 1:55 PM

7 0

U.S. top court rejects hepatitis B drug patent case

WASHINGTON (Reuters) - The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B.

The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent.

Also read: Court: Firms have duty to protect households from asbestos

Read more

To category page

Loading...